Biopharmaceuticals Manufacturing Consumables Testing Business Research Report 2024-2030
18 oct. 2024 04h30 HE
|
Research and Markets
Dublin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Manufacturing Consumables Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...
CAR-T Cell Therapy Market Research 2024: Regulatory Approvals, Pricing, Reimbursement, Degree of Market Penetration, Mergers and Acquisitions, IPOs, and Financing Events
16 oct. 2024 04h02 HE
|
Research and Markets
Dublin, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. ...
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
15 oct. 2024 04h30 HE
|
invIOs GmbH
Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
11 oct. 2024 06h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
Immatics Announces Pricing of $150 Million Public Offering
10 oct. 2024 20h50 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed $150 Million Public Offering
10 oct. 2024 07h30 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
10 oct. 2024 06h30 HE
|
https://immatics.com/
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily...
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
09 oct. 2024 09h05 HE
|
Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
08 oct. 2024 07h00 HE
|
KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
04 oct. 2024 09h00 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development...